Stephanie Planque has completed her PhD in 2009 from the University of Texas Health Science Center and postdoctoral studies from the same institution. She is an Assistant Professor at the University of Texas Health Science Center and holds a Scientific Adviser title at Covalent Bioscience, Inc, a start-up company that holds the intellectual property for catalytic and irreversible antibody technology and electrophilic vaccine technology. She has published more than 48 papers in reputed journals. Her primary area of research has focused on developing chemically reactive antibodies as therapeutic agents for infectious and amyloidosis-related diseases and chemically reactive antigens as vaccine for intractable diseases such as HIV. Stephanie Planque has completed her PhD in 2009 from the University of Texas Health Science Center and postdoctoral studies from the same institution. She is an Assistant Professor at the University of Texas Health Science Center and holds a Scientific Adviser title at Covalent Bioscience, Inc, a start-up company that holds the intellectual property for catalytic and irreversible antibody technology and electrophilic vaccine technology. She has published more than 48 papers in reputed journals. Her primary area of research has focused on developing chemically reactive antibodies as therapeutic agents for infectious and amyloidosis-related diseases and chemically reactive antigens as vaccine for intractable diseases such as HIV.

Vaccine, Immunology